Αρχική World News Low Risk of Cardiotoxicity with Immune Checkpoint Inhibitor Monotherapy or Combination Treatment

Low Risk of Cardiotoxicity with Immune Checkpoint Inhibitor Monotherapy or Combination Treatment

The incidence of cardiac adverse events is low with immune checkpoint inhibitor (ICI) treatment, administered either as a single agent or as a dual agent combination, and is not statistically different to that observed with non-ICI treatment for patients with diverse cancer types. These findings from a large meta-analysis of randomised clinical trials were presented at the ESMO Immuno-Oncology Virtual Congress 2020, held from 9 to 12 December 2020.

Elisa Agostinetto of the Academic Trials Promoting Team, Institut Jules Bordet in Brussels, Belgium and colleagues remarked that the risk of cardiotoxicity had been poorly investigated, especially whether ICI combinations increase cardiotoxicity compared to treatment with ICI monotherapy, thus prompting this meta-analysis. 

The primary objective of this study was to evaluate the cardiotoxicity with ICI therapy as compared to other cancer treatments, and the second objective was to determine the cardiotoxicity of dual agent ICI immunotherapy combinations versus single agent ICI.

Dr Agostinetto and colleagues conducted this systematic review and meta-analysis according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines that was registered in the PROSPERO database (CRD42020183524). The investigators performed a systematic search of the PubMed, MEDLINE, and EMBASE databases, as well as conference proceedings up to 30 June 2020. They identified all randomised clinical trials referencing all solid tumour types comparing an ICI against other treatments to satisfy the primary objective and also identified dual agent ICI compared to single agent ICI to meet the secondary objective. Pooled risk ratios (RR) with 95% confidence intervals (CI) for cardiotoxicity events were calculated using random effect models. Two separate and distinct meta-analyses were performed to address the primary and secondary objectives.

The analysis comprised 80 studies with 35,337 patients, of which 66 studies with 34,664 patients were focused towards the primary objective and 14 studies with 673 patients supported the secondary objective.

No statistically significant differences in the frequency of cardiac adverse events (AEs) were observed between the ICI and non-ICI treatment groups, nor between the dual ICI and single agent ICI treatment groups.

Overall, any cardiac AEs occurred in ≤4% of patients and myocarditis in ≤0.2% of patients (Table 1).


Table 1. Number of cardiac adverse events per number of patients, pooled incidence, and relative risk-ratios with 95% confidence intervals in the immune-checkpoint inhibitors (ICI) group vs non-ICI group and in the dual-ICI group vs single-ICI group.

© Elisa Agostinetto.

Specifically, the pooled incidence of any cardiac AE was 3.78% in the cohort treated with an ICI compared to 3.40% in the group receiving other, non-ICI treatment (RR 1.14; 95% CI 0.88-1.48).

With ICI versus non-ICI treatments, the pooled incidence for arrhythmias was 1.79 versus 1.49, respectively (RR 1.32; 95% CI 0.94-1.84). The pooled incidence for several other cardiotoxicities was less than 1.00 in either treatment group with lower RR, including myocarditis (0.12 vs 0.01; RR 1.11), myocardial infarction (0.41 vs 0.27; RR 1.19), pericarditis (0.51 vs 0.22; RR 1.14), heart failure (0.43 vs 0.63; RR 0.61), valvular disease (0 vs 0.03; RR 0.63), cardiac arrest (0.24 vs 0.09; RR 1.23), and cardiac death (0.33 vs 0.21; RR 1.07).

Regarding the secondary objective comparing cardiotoxicity in patients treated with an ICI combination versus those receiving single ICI therapies, the pooled incidence for any cardiac AE was 2.87 versus 0.40, respectively (RR 1.91; 95% CI 0.52-7.01). Again, the highest incidence was observed for arrhythmias of 2.48 with dual ICI versus 0 for single ICI treatment (RR 1.65; 95% CI 0.40-6.89). The incidence regarding all other cardiotoxicity was less than 1 in either treatment arm: myocarditis (0.17 vs 0; RR 1.10), myocardial infarction (0.50 vs 0; RR 0.98), pericarditis (0 vs 0.49; RR 0.67), heart failure (0.38 vs 0; RR 1.04), valvular disease (0 vs 0; RR 0.79), cardiac arrest (0 vs 0; RR 0.79), and cardiac death (0.27 vs 0; RR 1.28).

Of note, these observations remained consistent across subgroup analyses by tumour type, setting of disease, treatment line, and type of treatment where no statistically significant differences were found between the ICI versus non-ICI treatment or between combination versus single ICI therapy.

This study is the largest meta-analysis to date of cardiotoxicity induced by ICI,  investigating not only myocarditis events, which are known to have a potential immune-related aetiology, but also a broader range of cardiac AEs including myocardial infarction, pericarditis, heart failure, arrhythmias, valvular disease, cardiac arrest and cardiac death.

Nonetheless, the authors specify that not all studies included in the meta-analyses provided complete data about cardiac AEs among participants. Several studies presented only AEs occurring above a specified incidence, which might have ranged from 1% to 20%. This could favour underreporting of rare AEs, like cardiac events, and could mask the real incidence of this toxicity. Standardisation of AEs reporting should be a priority in clinical trials.


Importantly, the authors concluded that the use of an immune checkpoint inhibitor as a single agent or in combination regimens was not associated with increased risk of cardiotoxicity. However, despite the apparent cardiac safety of ICI, investigators of clinical trials should be strongly encouraged to report cardiac AEs systematically and as completely as possible.

No external funding was disclosed. 


41P – Agostinetto E, Eiger D, Lambertini M, et al. Cardiotoxicity of immune checkpoint inhibitors: A meta-analysis of randomized clinical trials. ESMO Immuno-Oncology Virtual Congress 2020 (9-12 December).



Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like

Διαβαστε Επίσης


Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...


ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...

Καρκίνος: Ευεργετική για τους καρκινοπαθείς η άσκηση

Σημαντικά ωφέλη προσφέρει η άσκηση, ακόμη και σε ασθενείς με καρκίνο. Οι περισσότεροι ασθενείς αγνοούν τα οφέλη που μπορεί να έχει γι’ αυτούς η συχνή...
- Advertisment -

Ροή Ειδήσεων

Final Results of the Collaborative EORTC/Intergroup Randomised Phase III Study of Adjuvant Imatinib in Localised GIST

Final analysis of the EORTC Soft Tissue and Bone Sarcoma Group, the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and...

Pink Van Makes the Rounds Throughout Rural New Zealand to Offer Free Breast Health Advice

Many of us have questions about breast cancer prevention or screenings. Getting lost in a Google rabbit hole can sometimes be overwhelming and could...

How My Inherited Cancer Diagnosis Has Made Me a Better Oncologist

Dr. Lewis is Director of Gastrointestinal Oncology at Intermountain Healthcare Utah; Vice President of American Multiple Endocrine Neoplasia Support; Head of the Communications Committee...

FDA Approves Cemiplimab-rwlc for Advanced Non-Small Cell Lung Cancer With High PD-L1 Expression

On 22 February 2021, the US Food and Drug Administration (FDA) approved cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals, Inc.) for the first-line treatment of patients with...

Five-Year Outcomes with CAR T Cell Therapy

The results of 5-year follow-up in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma who were treated with CD19-directed,...

Countdown to 100,000 OncoLife Survivorship Care Plans: How it all started

In April of 2007, OncoLink launched the OncoLife Survivorship Care Plan, a tool to create care plans for people who have survived cancer. As...